The big wins have piled up recently for Winston & Strawn’s intellectual property team. In April, Winston’s James Hurst won a 9-0 ruling for client Caraco Pharmaceutical Laboratories Ltd. at the U.S. Supreme Court in a case that opens a new pathway for generic drug companies to challenge the accuracy of patent information name-brand companies give to the U.S. Food and Drug Administration. The defeat of Danish name-brand pharmaceutical firm Novo Nordisk A/S was just one of a string of wins for generic drug companies.
Hurst also scored a victory for client Sun Pharmaceutical Industries. In 2010, the U.S. Court of Appeals for the Federal Circuit invalidated a patent on one of Eli Lilly and Co.’s highest-selling cancer drugs, known as Gemzar. The court agreed with Sun’s argument that Lilly had engaged in “double-patenting.” Last May, the Supreme Court denied Lilly’s cert petition in the case.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
